Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient Sa Rang Kim, BSc, Nour Kibbi, MD, Brittany G. Craiglow, MD JAAD Case Reports Volume 5, Issue 6, Pages 552-554 (June 2019) DOI: 10.1016/j.jdcr.2019.04.014 Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Response to guselkumab. A, Back with sharply demarcated pink-red scaly plaques, which were persistent despite treatment with methotrexate, adalimumab, and ustekinumab. B, Back with postinflammatory hyperpigmentation. There has been near complete resolution of psoriasis after 5 months of treatment with guselkumab. JAAD Case Reports 2019 5, 552-554DOI: (10.1016/j.jdcr.2019.04.014) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions